Abstract
Both animal and in vitro studies have demonstrated that combinations of flucytosine with amphotericin B and with fluconazole have significantly improved activity against cryptococcal meningitis compared with the activity of each drug used alone. However, very few dose levels of these agents have been tested in combination. This study evaluated the efficacy of fluconazole plus flucytosine in a murine model of cryptococcal meningitis over a broad range of dose combinations (fluconazole, 0 to 40 micrograms/g of body weight per day; flucytosine, 0 to 200 micrograms/g/day). Both drugs were dissolved in drinking water, with treatment on days 2 to 11. In this highly reproducible model, fluconazole had a dramatic effect on the fungicidal activity of flucytosine. Flucytosine at dose levels of as much as 200 micrograms/g/day alone or in combination with low doses of fluconazole had minimal fungicidal activity, whereas in combination with fluconazole at 24 to 40 micrograms/g/day, flucytosine showed fungicidal activity in the range of 45 to 65% of the animals treated at doses of 40 to 100 micrograms/g/day. This striking effect of fluconazole is consistent with the results of both in vitro and clinical studies. In the clinic, the use of flucytosine is often limited by severe toxicity, while toxicity is rarely observed with fluconazole. These results suggest that when flucytosine is given with higher doses of fluconazole, the maximum therapeutic effect of the former in the clinic may be observed at dose levels that are far less than the doses commonly employed (150 micrograms/g daily).
Full Text
The Full Text of this article is available as a PDF (231.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Allendoerfer R., Marquis A. J., Rinaldi M. G., Graybill J. R. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1991 Apr;35(4):726–729. doi: 10.1128/aac.35.4.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
- Berry A. J., Rinaldi M. G., Graybill J. R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992 Mar;36(3):690–692. doi: 10.1128/aac.36.3.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larsen R. A., Bozzette S. A., Jones B. E., Haghighat D., Leal M. A., Forthal D., Bauer M., Tilles J. G., McCutchan J. A., Leedom J. M. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):741–745. doi: 10.1093/clinids/19.4.741. [DOI] [PubMed] [Google Scholar]
- Larsen R. A., Leal M. A., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med. 1990 Aug 1;113(3):183–187. doi: 10.7326/0003-4819-113-3-183. [DOI] [PubMed] [Google Scholar]
- Link C. L. Confidence intervals for the survival function using Cox's proportional-hazard model with covariates. Biometrics. 1984 Sep;40(3):601–609. [PubMed] [Google Scholar]
- Nguyen M. H., Barchiesi F., McGough D. A., Yu V. L., Rinaldi M. G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother. 1995 Aug;39(8):1691–1695. doi: 10.1128/aac.39.8.1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Grieco M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83–89. doi: 10.1056/NEJM199201093260202. [DOI] [PubMed] [Google Scholar]
- Stamm A. M., Diasio R. B., Dismukes W. E., Shadomy S., Cloud G. A., Bowles C. A., Karam G. H., Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug;83(2):236–242. doi: 10.1016/0002-9343(87)90691-7. [DOI] [PubMed] [Google Scholar]
- Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 1993 Aug;168(2):508–510. doi: 10.1093/infdis/168.2.508. [DOI] [PubMed] [Google Scholar]